These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8095924)

  • 1. T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.
    Sundstrom JB; Cherniak R
    Infect Immun; 1993 Apr; 61(4):1340-5. PubMed ID: 8095924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen.
    Sundstrom JB; Cherniak R
    Infect Immun; 1992 Oct; 60(10):4080-7. PubMed ID: 1398921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
    Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
    J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
    Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
    Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
    Blackstock R; Casadevall A
    Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO; May RJ; Valadon P; Scharff MD
    J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
    Brandt S; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
    Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronoxylomannan of Cryptococcus neoformans exacerbates in vitro yeast cell growth by interleukin 10-dependent inhibition of CD4+ T lymphocyte responses.
    Mariano Andrade R; Monteiro Almeida G; Alexandre DosReis G; Alves Melo Bento C
    Cell Immunol; 2003 Apr; 222(2):116-25. PubMed ID: 12826081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ; Beenhouwer DO; Scharff MD
    J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
    Martinez LR; Moussai D; Casadevall A
    Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
    Blackstock R
    Immunology; 2003 Feb; 108(2):158-66. PubMed ID: 12562324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
    Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
    Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans.
    Retini C; Kozel TR; Pietrella D; Monari C; Bistoni F; Vecchiarelli A
    Infect Immun; 2001 Oct; 69(10):6064-73. PubMed ID: 11553544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.